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Effect of prostaglandin E administration in a nephrotoxic and a
vasoconstrictor model of acute renal failure. It is generally thought
that renal vasoconstriction is involved in the generation of acute
renal failure (ARF). To test this hypothesis, two models of experi-
mental ARF, uranyl nitrate-induced ARF and the unilateral in-
fusion of norepinephrine, were investigated. Prior to the induction
of acute renal failure, renal blood flow (RBF) was markedly in-
creased in one kidney by the intrarenal infusion of prostaglandin
E, (POE), In the uranyl nitrate studies, RBF in the POE-infused
kidney was markedly elevated throughout the three-hour period
after administration of the nephrotoxic drug. Mean values were
171 mI/mm prior to POE infusion and 308 mI/mm three hours
after the administration of uranyl nitrate (P < 0.005), while in the
control kidney, blood flow fell slightly from 164 to 143 mI/mm.
The fractional distribution of blood flow to the outer cortex,
measured with radioactive microspheres, decreased significantly (P
<0.05) in the POE-infused kidney but remained unchanged in the
control kidney three hours after uranyl nitrate infusion. In spite of
these differences in total and regional blood flow, inulin clearance
fell similarly in both kidneys at three hours from 40 to 24 (P <
0.005) and 43 to 28 mI/mm (P < 0.005) in the POE-infused and
control kidney, respectively. Utilizing a similar protocol, inulin
clearance was reduced equally in both kidneys 48 hr after uranyl
nitrate infusion. In the norepinephrine studies, RBF was reduced
to an undetectable level, as measured by flowmeter during the
administration of the vasoconstrictor, and inulin clearance was
decreased to 7% of the control value three hours after the infusion
of norepinephrine (P <0.001). When PGE was administered prior
to and during norepinephrine infusion, RBF was similarly de-
creased during norepinephrine, but inulin clearance was reduced to
a lesser extent three hours after discontinuing the vasoconstrictor
than when norepmnephrmne was given alone, —48% vs. —93% (P <
0.005). Infusion of PGE prior to, during, and for the three-hour
period after norepinephrine had a similar protective effect, even
though renal hemodynamics was more rapidly and completely
restored in this model. When POE was given only during the
norepinephrine infusion, inulin clearance fell as much as it did with
norepinephrine alone. These findings indicate that marked renal
vasodilatation does not obviate the acute reduction in inulin clear-
ance after uranyl nitrate infusion. In contrast, a prior infusion of
POE does attenuate the development of renal functional impair-
ment after intrarenal norepinephrine, even though the vasodilator
does not alter the marked increase in renal resistance during nor-
epinephrine infusion.
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L'effet de I'administration de prostaglandine E dans un modéle
d'insuffisance rénale aiguë par néphrotoxicité et vasoconstriction. II
est genéralement admis que Ia vasoconstrietion rénale est impli-
quée dans Ic déterminisme de l'insuffisance rénale aiguë (ARF).
Afin d'étudier cette hypothèse deux modéles d'ARF expérimentale
ont été étudiés, I'ARF déterminée par Ic nitrate d'uranyle et celle
obtenue par Ia perfusion unilatérale de norépinéphrine. Avant
I'induction de I'ARF Ic debit sanguin renal d'un rein a été augmen-
té de facon importante par Ia perfusion intrarénale de prostaglan-
dine E2 (POE). Au cours des experiences avec Ic nitrate d'uranyle,
le debit sanguin renal du rein perfuse avec POE a été augmente de
façon importante pendant une période de trois heures aprés
l'administration de l'agent néphrotoxique. Les valeurs moyennes
étaient de 171 mI/mm avant POE et 308 mI/mm trois heures aprés
l'administration de nitrate d'uranyle (P < 0,005) alors que Ic debit
du rein contrôle a diminué de 164 a 143 mI/mm. La fraction du
debit sanguin renal délivrée au Cortex superficiel a diminué signifi-
cativement (P < 0,05) dans le rein perfuse avec POE mais n'était
pas modifiée dans le rein contrôle trois heures après le nitrate
d'uranyle. Malgré ces differences dans les debits totaux et régio-
naux Ia clearance de I'inuljne était diminuée de facon similaire dans
les deux reins, a Ia troisième heure, de 40 a 24 (P < 0,005) et de 43 a
28 mI/mm (P < 0,005) dans les reins perfusés avec POE et con-
trôles respectivement. Dans un protocole semblable Ia clearance de
l'inuline était réduite de façon équivalente dans les deux reins 48 hr
après le nitrate d'uranyle. Dans les experiences oO Ia norépinéph-
rine a été utilisée le debit sanguin renal était réduit a une valeur non
mesurable au débitmétre au cours de l'administration du vaso-
constricteur et Ia clearance de l'inuline Ctait égale a 7% de Ia valeur
contrôle trois heures aprés Ia perfusion de norepinéphrine (P <
0,001). Quand Ia POE a été administrCe avant et pendant Ia per-
fusion de norépinéphrine le debit sanguin renal a été réduit de
facon similaire mais Ia reduction de Ia clearance de I'inuline Ctait
moindre, trois heures après l'arrCt du vasoconstricteur, que lors de
l'administration de norépinéphrine seule: —48% au lieu de —93%.
La perfusion de POE avant, pendant et pendant trois heures après
I'administration de norépinéphrine a eu un effet protecteur sim-
ilaire bien que I'hémodynamique rénale ait été rétablie plus rapid-
ement et plus complètement dans cc modèle. Quand Ia PGE a été
administrée seulement pendant Ia perfusion de norépinéphrine Ia
clearance de l'inuline a diminué de Ia méme facon qu'avec Ia
norépinéphrine seule. Ces constatations indiquent qu'une vasodila-
tation rCnale importante n'empéche pas Ia diminution de Ia clear-
ance de I'inuline aprés nitrate d'uranyle. Au contraire, une per-
fusion préalable de POE atténue Ic développement de I'insuffisance
rCn ale liée a Ia perfusion de norépinéphrine bien que le vasodilata-
teur n'empêche pas l'augmentation importante de Ia résistance
rénale au cours de Ia perfusion de norépinéphrine.
The pathophysiologic mechanisms involved in the
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initiation and maintenance of acute renal failure are
not clear. One factor, however, which most in-
vestigators have felt was associated with the develop-
ment of acute renal failure is renal vasoconstriction
[1—5]. Although it is true that this hemodynamic al-
teration is present initially or during the maintenance
period of most experimental models of acute renal
failure [3—5], its role in producing renal functional
impairment has not been adequately tested. Lade-
foged and Winkler [6] and Hollenberg et al [7] have
shown that the administration of vasodilators can
markedly increase renal blood flow in patients with
acute renal failure. A similar decrease in renal resist-
ance has been noted by Jaenike [8], Fung and Thom-
son [9], Arendshorst, Finn, and Gottschalk [10], and
Cox et al [11] with either drug-induced renal vasodi-
lation or saline-loading in various experimental mod-
els of acute renal failure. Yet, in none of these studies
was there any discernible increase in glomerular fil-
tration rate as renal resistance was decreased. It
should be emphasized, however, that in all of these
studies, acute renal failure was already established at
the time of the intervention. There are no data avail-
able on the possible protective effect of renal vasodi-
lation in the initial phase of acute renal failure.
Therefore, the present study was designed to deter-
mine whether the administration of a potent renal
vasodilator, prostaglandin E2 (PGE), prior to the
onset of acute renal failure could modify the initial
alteration in renal function or the eventual develop-
ment of acute renal failure. The effect of renal vaso-
dilatation was evaluated in a nephrotoxic model,
uranyl nitrate administration, and a model which
causes renal failure primarily by hemodynamic
means, the intrarenal administration of norepin-
ephrine. The results indicate that intrarenal PGE
administration has a protective effect only in the
latter model.
Methods
Studies were performed on mongrel dogs, weighing
14 to 24 kg. The dogs were anesthetized with sodium
pentobarbital (30 mg/kg of body wt). An endotra-
cheal tube was inserted and the animals were venti-
lated with a Harvard respirator. Cannulas were in-
serted in a leg vein for infusion and in the femoral
artery for blood pressure measurement and blood
collection. A catheter (Goodale-Lubin) was threaded
into the left ventricle for the injection of radioactive
microspheres. Both ureters were cannulated through
a suprapubic incision. A 25-guage needle was inserted
at the origin of the renal artery through a small left
flank incision for drug infusion and was kept open
with Ringer's solution at 0.5 ml/min. In most studies,
an electromagnetic flow probe (Zepeda Instruments,
Seattle, WA) was placed on the renal artery for the
purpose of continuously monitoring renal blood
flow. The flowmeter was calibrated in vitro, and the
zero point was frequently checked during a study by
occluding the renal artery distal to the flow probe. An
infusion of Ringer's solution containing 2.5% inulin
was given at 0.5 ml/min, and additional Ringer's
solution was infused at a rate which approximated
urinary losses throughout the study.
Total renal blood flow was also measured in most
studies with an indicator dilution modification of the
radioactive microsphere method, as previously de-
scribed [12]. The nuclides used were scandium 46
(46Sc), cerium 141 ('41Ce), and strontium 85 (85Sr). A
different nuclide was used in each period, and the
sequence of injection was altered from experiment to
experiment.
Seven groups of studies were performed. In groups
I to 3, renal functional impairment was induced by
uranyl nitrate, while in the later four groups, intra-
renal norepinephrine was utilized.
Since the design of this study was to attempt to
produce marked and prolonged renal vasodilatation
during the initial phase of acute renal failure, prelimi-
nary studies were performed with several renal vaso-
dilators. PGE was found to be the most stable and
consistent of these agents and was therefore utilized
in the present study.
Group 1: Control studies (N = 4). After control
clearances and a first microsphere injection was
given, PGE (9 ig/min) was given in the left renal
artery. Blood flow was then continuously monitored;
and three hours later, repeat clearance and micro-
sphere determinations were performed.
Group 2: Acute uranyl nitrate studies (N = 6). After
control clearances were obtained and the first micro-
sphere injection was given, PGE (9 g/min) was ad-
ministered in the left renal artery and was continued
throughout the study. Shortly after the PGE infusion
was begun, uranyl nitrate (5 mg/kg) was adminis-
tered i.v. Renal blood flow was then constantly mon-
itored by the electromagnetic flowmeter, and three
hours later a second microsphere injection and
clearance collections were obtained.
Group 3: Chronic uranyl nitrate studies (N = 6). In
this group of studies the development of renal func-
tional impairment 48 hr after uranyl nitrate infusion
was evaluated with the same protocol as in group 2.
The animals were anesthetized, a control microsphere
injection was given, and a serum creatinine was ob-
tained. The infusion of PGE and uranyl nitrate were
the same as in group 2, and a second microsphere
injection was given at the end of the three-hour PGE
infusion. The flow probe and renal artery needle were
then removed; the animals were returned to their
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cages and restudied 48 hr later. At this time, they
were anesthetized and bilateral ureteral catheters
were placed. Inulin clearance and a third microsphere
determination were then obtained, as well as a repeat
serum creatinine.
Group 4: Norepinephrine (N = 6). After control
clearances and a microsphere injection, norepineph-
rifle (1 g/kg/min) was given in the left renal artery
for 40 mm. Three hours later, repeat clearance collec-
tions and another microsphere injection were per-
formed.
Group 5: Norepinephrine plus prior and simultane-
ous studies (N = 13). After control measurements,
PGE (9 g/min) was infused in the left renal artery 15
mm before norepinephrine administration and was
continued throughout the 40-mm norepinephrine in-
fusion. Then, both vasoactive agents were discontin-
ued, and three hours later repeat clearances were
obtained and a microsphere injection was given. Five
additional studies were performed with this protocol
in which only blood flow was measured with micro-
spheres during the simultaneous administration of
norepinephrine plus PGE. This group of studies was
performed to determine quantitatively absolute
blood flow during the administration of the vaso-
constrictor. Since flow was exceedingly low, only one
sphere was utilized in order to obviate the problems
of subtracting the radioactive crossover of the nu-
clides.
Group 6: Norepinephrine plus continuous PGE stud-
ies (N = 6). This protocol was similar to that utilized
in group 5, with the exception that the PGE infusion
was continued throughout the three-hour period after
discontinuation of the norepinephrine.
Group 7. Norepinephrine plus simultaneous PGE
studies (N = 5). This protocol was similar to that
utilized in group 5, with the exception that the PGE
infusion was started at the same time as the norepi-
nephrine, rather than 15 mm before, and was con-
tinued throughout the 40 mm of norepinephrine
infusion. A single microsphere was given in this group
during the PGE and norepinephrine infusion to more
accurately determine whether any measurable amount
of blood was reaching the experimental kidney during
this period.
At the conclusion of all experiments, the kidneys
were removed and handled by methods previously
described [13]. Total blood flow was measured with
the radioactive microsphere method as well as the
fractional distribution of cortical blood flow in the
group 2 studies. In these latter studies, the cortex was
divided into four equal zones, which will be called
zones I through IV, going from outer to inner cortex,
respectively. The tissue sections were counted as pre-
viously described [11].
Plasma and urine inulin concentrations were deter-
mined by the anthrone method [14] as modified for
the autoanalyzer (Technicon, Technical Instruments,
Tarrytown, NY). Urinary sodium concentration was
measured with flame photometer (Instrumentation
Laboratory, Inc., Watertown, MA).
Calculations. I) Renal blood flow (RBF) as de-
termined by microspheres was calculated by the
following formula:
RBF, mI/mm
Total cpm in kidney
Blood withdrawal rate, mI/mm
Total cpm in blood
where cpm = counts per minute of the nuclide. 2) The
methods of calculating the corrected fractional distri-
bution of renal cortical blood flow per cortical zone
and the zonal perfusion rate have been described
previously [13].
Standard statistical analysis was used, and all data
are presented as the mean SEM.
Results
Group 1: Control studies. In these four studies,
control renal blood flow averaged 213 24 mI/mm
(as determined by electromagnetic flowmeter). Blood
flow rose immediately in all four studies after the
PGE infusion was begun and remained elevated at
374 60, 343 58, 345 60, and 341 58 ml/min
30, 60, 120, and 180 mm after the start of the PGE
infusion, respectively. All of these values were signifi-
cantly greater than in the control period (P < 0.05 or
less). Similar changes were found before and three
hours after the initiation of the PGE infusion by the
microsphere method in two of these studies (171 vs.
360 mI/mm and 180 vs. 309 mI/mm). Inulin clear-
ance, however, remained unchanged, 41 7 vs. 43
6 mI/mm in the control and three-hour collection
period, respectively. The inulin clearance was also
unchanged in the contralateral kidney. Thus, an in-
trarenal infusion of PGE for three hours did not alter
inulin clearance during this time period.
Group 2: A cute uranyl nitrate studies. The results of
these studies are summarized in Table 1 and Figures 1
to 3. Blood pressure remained unchanged throughout
the study. Urine flow increased from 0.8 0.3
mI/mm in the control period to 3.3 0.8 mI/mm
three hours after uranyl nitrate infusion in the PGE-
infused kidney (P < 0.01). Sodium excretion also
rose in five of the six studies in the experimental
kidney, with a mean change from 188 67 to 397
93 tEq/min. This change was just below the 0.05
level of significance. No significant change in either
parameter was noted in the contralateral kidney three
hours after uranyl nitrate. As can be noted in Table 1,
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Table 1. Summary of acute uranyl nitrate studies (group 2)8
lnulin clearance, mi/mm RBF, mi/mm BP, mm Hg
Exp.
no. C
Left
E C
Right
E C
Left
E
Right
C EC E
1
2
3
4
5
6
32
43
35
41
58
33
23 31
16 47
14 32
28 39
43 61
25 45
23
21
17
20
48
37
143
171
137
188
252
134
216
310
381
294
364
380
134
175
124
161
248
145
101
130
191
116
196
125
150
130
170
160
140
170
165
120
160
175
130
150
Mean
P
40
4
24 43
4 5
<0.005 <0.005
28
5
171
18
<0.005
308
24
164
18
NS
143
16
153
6
NS
150
8
8 Abbreviations used are: RBF, renal blood fibw; left and right refer to kidneys; C, control period; E, experimental period; NS, not significant.
renal blood flow was markedly increased in the PGE-
infused kidney three hours after uranyl nitrate. As
determined with the radioactive microsphere method,
renal blood flow was 171 mI/mm in the control pe-
riod and rose to 308 mI/mm three hours after uranyl
nitrate, P < .005. In addition, total blood flow in the
experimental kidney was monitored continuously
with an electromagnetic flowmeter in five of the six
studies. Blood flow remained markedly elevated
throughout the entire three-hour period after uranyl
nitrate. Control flow was 170 mI/mm and was ele-
vated at 297, 276, 277, and 277 mI/mm 30, 60, 120,
and 180 mm after uranyl nitrate infusion, respec-
tively. Thus, uranyl nitrate, 5 mg/kg, did not over-
come the vasodilatory effect of PGE. In fact, as is
shown in Figure 1, the percent of increase in total
C
I
renal blood flow after PGE in these uranyl nitrate
studies was quite comparable to that in the group 1
studies 30, 60, 120, and 180 mm after the initiation of
the PGE infusion. In contrast, total renal blood flow
decreased at three hours in the contralateral kidney in
five of the six studies, with a mean change from 164 to
143 mi/mm (Table 1). Yet, in spite of the marked
difference in renal blood flow between the control
and PGE-infused kidney three hours after uranyl ni-
trate, the change in inulin clearance was quite similar
(Table 1). In the experimental kidney, inulin clear-
ance fell from 40 to 24 mI/mm (P < 0.005), while in
the control kidney, inulin clearance decreased from
43 to 28 mI/mm (P < 0.005) three hours after uranyl
nitrate infusion, There was no difference in the
change in inulin clearance between the two kidneys.
The fractional distribution of renal cortical blood
flow was also determined in both kidneys in these
studies (Fig. 2). In the experimental kidney, the frac-
tional distribution of cortical blood flow decreased in
outer cortical zone I from 42 to 31% (P < 0.05) and
increased 2, 4, and 5% in zones II to IV, respectively.
The changes in inner cortical zones III and IV were
just below the level of statistical significance. As
shown in Figure 3, zonal perfusion rate was un-
changed in zone I but rose significantly in zones II to
IV in the vasodilated kidney. In contrast, there was
no change in either the fractional distribution of flow
or the zonal perfusion rate in the contralateral con-
trol kidney (Figs. 2 and 3). Thus, in spite of marked
differences in total renal blood flow and the fractional
distribution of cortical flow between the two kidneys,
the fall in inulin clearance was comparable three
hours after uranyl nitrate infusion.
Group 3: Chronic uranyl nitrate studies. This group
of studies was designed to determine whether renal
functional impairment would persist and be evident
48 hr after uranyl nitrate when a protocol similar to
that in group 2 was utilized. The results of these
- P<0.05
P<0.005
100
90
80
70
60
50
3
Time, hr
Fig. 1. The percent of change in renal blood flow (RBF) during PGE
alone ( ) vs. PGE + uranyl nitrate ( ) in the ex-
perimental kidney 30, 60, 120, and 180 mitt after initiating PGE.
126 Mauk et a!
Zone I Zone II Zone III Zone IV
Experimental kidney
Zone I Zone II Zone III Zone IV
Control kidney
Fig. 2. The fractional distribution of cortical blood flow before and
three hours after the administration of uranyl nitrate in the PGE-
infused experimental kidney and control kidney.
studies are summarized in Table 2. As can be noted,
renal blood flow was again increased at three hours in
the experimental kidney, 197 vs. 360 mI/mm (P <
0.05), and had returned to control levels 48 hr after
uranyl nitrate. In contrast, total flow decreased in
three or four studies at three hours in the contra-
lateral kidney but had returned to control levels at
48 hr (Table 2). Yet, in spite of these marked differ-
ences in total flow three hours after uranyl nitrate,
inulin clearance was markedly reduced at 48 hr in
both kidneys, 2.7 and 2.5 mI/mm in the experimental
and control kidney, respectively. Both of these values
are markedly less than the control values obtained in
dogs of comparable weight and kidney size during the
control period of group 2 (P < 0.001) but not differ-
ent from each other. Thus, a marked increase in renal
blood flow during the first three hours after uranyl
nitrate does not prevent the initial fall in inulin clear-
ance or the marked suppression in renal function 48
hr later.
Group 4: Norepinephrine studies. These and the fol-
lowing three groups of studies are summarized in
Table 3. During the 40-mm infusion of norepineph-
rifle, renal blood flow as measured by flowmeter was
essentially zero, and there was no urine flow. In four
studies, blood flow was also measured with radio-
active microspheres during the norepinephrine in-
fusion and averaged 3.9 1.5 mI/mm. Blood flow
and urine flow remained essentially zero for 45 to 60
mm after discontinuing norepinephrine before be-
coming measurable again. Three hours after norepi-
nephrine, urine flow had returned to or above control
levels in three studies and had decreased in three
experiments. Renal blood flow still remained below
control levels, 121 vs. 175 mI/mm, P < 0.05. In
addition, inulin clearance was markedly reduced in
each study, with a change from a mean value of 38
mI/mm in the control period to a mean value of 3
mI/mm three hours after norepinephrine infusion (P
< 0.001). The inulin clearance three hours after nor-
epinephrine infusion was 7% of the control value
(range, 0 to 14%). In contrast, inulin clearance in the
contralateral kidney was unchanged, 45 5 vs. 46
7 ml/min in the control and three-hour period after
norepinephrine, respectively.
Group 5: Norepinephrine plus prior and simultane-
ous PGE studies. In these studies, an intrarenal in-
fusion of PGE was begun 15 mm prior to the start of
the norepinephrine infusion and was continued
throughout the infusion of the vasoconstrictor. Blood
-F
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N= 6
P<0.05
--±-
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.0
C0N
0
00
.0
C,C0N
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30
20
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50• I N=6
1
N=6
P<0.025
•CCP<001
10
C, 8
C,
6
-E 4
0N 2
10
C 8
C,
E 4
C0N 2
Zone IVZone I Zone II Zone III
Experimental kidney
N=6
rn
Zone I Zone II Zone III Zone IV
Control kidney
Fig. 3. The zonal perfusion rate before and three hours after the
administration of uranyl nitrate in the PGE-infused experimental
kidney and control kidney.
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Table 2. Summary of chronic uranyl nitrate studies (group 3)
Exp.
no.
Inulin clearance
mi/mm
L R
RBF,m//min
Serum creatinine
mg/lOOml
C E C
BP,mmHg
E
L R
C 3hr 48hr C 3hr 48hr
1 8.1 4.6 203 513 321 194 209 279 0.6 3.1 130 125
2 0.01 0.002 175 271 180 135 75 178 0.6 6.2 110 125
3 0.02 0.1 268 308 138 183 111 161 0.8 6.4 110 85
4 2.5 1.2 135 — 154 136 — 183 0.7 4.5 125 110
5 0.6 0.3 165 346 138 161 147 133 0.6 3.2 135 110
6 5.0 9.0 235 — 254 280 — 242 0.7 4.5 140 130
Mean 2.7 2.5 197 360 198 182 136 196 0.7 4.7 135 114
SEM 1.3 1.5 20 53 30 22 28 22 0.03 0.6 5 6
P NS <.05 <.025 NS NS <.001 NS
Abbreviations used are: RBF, renal blood flow; HP, blood pressure; L, left kidney; R, right kidney; C, control period; E, experimental
period.
flow rose immediately after the PGE was begun, with
a mean increase of 59%. Yet, in spite of the adminis-
tration of the vasodilator, renal blood flow, measured
with flow probe, and urine flow fell immediately to
essentially zero after the norepinephrine infusion was
started. In five additional studies, total flow, as mea-
sured with microspheres during norepinephrine and
PGE infusion, was 4.8 2.4 mI/mm, a value not
significantly different from that found in the group 4
studies. Both urine volume and blood flow remained
at an unmeasurable level for 45 to 60 mm after the
discontinuation of the norepinephrine infusion, as in
group 4 studies, and then began to rise. At three
hours, total renal blood flow was still reduced in
comparison with control values, 101 vs. 166 ml/min
(P < 0.001) while urine flow and sodium excretion
were not significantly different from control. Inulin
clearance was also reduced in comparison to control
values, but the magnitude of the fall was considerably
less than in the group 4 studies (Table 3). The inulin
clearance in the group fell from 38 mI/mm in the
control period to 20 mI/rn in three hours after norepi-
nephrine (P < 0.02). The average reduction in inulin
clearance in this group of studies was 48% in com-
parison to the 93% fall in the group 4 studies. These
values were significantly different at the P < 0.005
level. Inulin clearance tended to increase on the con-
tralateral side, 37 mI/rn in in the control period vs. 43
mI/mm three hours after the discontinuation of the
norepinephrine infusion.
Thus, the administration of PGE prior to and dur-
ing the norepinephrine infusion significantly pro-
tected against the fall in inulin clearance three hours
after discontinuation of both drugs.
Table 3. Summary of norepinephrine studiesa.b
Group C
Inulin clearance
mi/mm
E
RBF
mI/mm
BP
mm Hg
C E C F
Group4:Norepinephrine(N=6)
PCE
GroupS: Norepinephrine + prior & simultaneous POE
(N=8)
PCE
Group 6: Norepinephrine + continuous PGE
(N=6)
PcE
PIv—vI
Group 7: Norepinephrine + simultaneous PGE
(N=5)
PCE
P1w_v
38
4
38
2
35
4
30
4
<0.001
<0.02
<0.005
<0.02
<0.005
<0.005
NS
3
1
20
3
16
2
2
2
175
15
166
11
188
17
—
<0.05
<0.001
NS
121
15
101
II
219
23
—
139
4
141
5
152
6
116
4
NS
NS
NS
NS
133
3
140
6
144
10
113
6
Abbreviations used are: RBF, renal blood flow; C, control period; E, experimental period.
b Results are mean + SEM of data obtained from norepinephrine infused kidney.p,, and P_v11 represent a comparison of the change in inulin clearance after norepinephrine in group 4 with the other three
groups.
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Group 6: Norepinephrine plus continuous PGE stud-
ies. In these studies, PGE was infused in the experi-
mental kidney 15 mm prior to, during, and for three
hours after the norepinephrine infusion. Total blood
flow rose 81% after PGE infusion. As in the previous
groups, however, blood flow (as measured by flow-
meter) and urine volume were zero during the norepi-
nephrine infusion. After discontinuing the norepi-
nephrine but continuing the PGE infusion, urine flow
and renal blood flow resumed in only 15 to 25 mm, a
shorter period than in the previous two groups of
studies. In addition, urine flow significantly increased
from 1.5 mI/mm in the control period to 3.5 ml/min
three hours after the norepinephrine infusion (P
< 0.02), and renal blood flow returned to control
levels (Table 3). Sodium excretion was not signifi-
cantly different from control levels. Yet, inulin clear-
ance was still markedly reduced in comparison with
control values, 16 vs. 35 mI/mm (P < 0.02). This
45% reduction in inulin clearance was not different
from the results of the group 5 studies but was sig-
nificantly less than in the group 4 studies (P < 0.005).
Inulin clearance on the contralateral kidney was 34
4 and 37 3 ml/min in the control and three
hour period, respectively.
Group 7.' Norepinephrine plus simultaneous PGE
studies. In these studies, PGE was given into the renal
artery only during the 40 mm of norepinephrine in-
fusion. During the infusion of the two drugs, blood
flow (as measured by radioactive microsphere) was
3.5 1.3 mI/mm in the experimental kidney. Urine
flow was zero during this 40-mm period. After stop-
ping both drugs, there was a gradual return of urine
flow to a mean value of 0.5 0.2 three hours after the
drugs were stopped, as compared to 0.4 mi/mm
during the control period. Inulin clearance was
markedly reduced from a mean value of 30 ml/min in
the control period to 2 mI/mm three hours after
discontinuation of both drugs, a 93% reduction in
inulin clearance. In contrast, inulin clearance on the
contralateral kidney was unchanged, 30 3 vs. 30
4 mI/mm in the control and three hour period after
drug administration, respectively. The fall in inulin
clearance in these studies was not different from the
values obtained when norepinephrine was given
alone (group 4) but was significantly greater than the
changes noted in either group 5 or group 6 when an
infusion of PGE was given prior to norepinephrine (P
<0.01).
Discussion
In the present study, PGE (a potent renal vasodila-
tor) was utilized to attempt to prevent vasoconstric-
tion in two different experimental models of acute
renal failure—uranyl nitrate administration and nor-
epinephrine infusion. PGE prevented the vasocon-
striction in the uranyl nitrate model and, in fact,
caused a profound fall in renal resistance throughout
the three-hour period after uranyl nitrate administra-
tion. In contrast, renal blood flow still fell to essen-
tially undetectable levels in the PGE-infused kidney
during norepinephrine administration. Yet, PGE in-
fusion had a protective effect on the change in inulin
clearance only in the norepinephrine studies. These
seemingly paradoxical findings will be discussed sepa-
rately.
Studies from this and other laboratories have dem-
onstrated that uranyl nitrate may cause a profound
increase in renal vascular resistance at least in the
initial three- to six-hour period after administration
[15, 16]. It therefore seemed possible that the progres-
sive renal functional impairment noted in this model
was linked to an alteration in renal resistance. In the
present study, however, renal blood flow was main-
tained at least 60% above the control level through-
out the three-hour period after uranyl nitrate in-
fusion. The magnitude of the increase in total blood
flow was quite comparable to that noted during a
similar three-hour period in the group I control ani-
mals (Fig. I). Yet, inulin clearance remained unal-
tered three hours after the start of the PGE infusion
in the control animals and fell approximately 40% in
the animals given uranyl nitrate. In addition, the fall
in inulin clearance in the PGE-infused kidney was not
different from that noted in the contralateral non-
vasodilated kidney (Table I). Thus, these findings
would strongly suggest that the initial fall in inulin
clearance after uranyl nitrate, at least in this particu-
lar model, was not primarily due to renal vasocon-
striction. These findings are compatible with a recent
micropuncture study by Blantz in the Munich-Wistar
rat [17]. He found a marked fall in inulin clearance in
the first six hours after uranyl nitrate infusion, despite
no change in renal plasma flow. The fall in inulin
clearance was found to be due to two factors: tubular
damage leading to back diffusion of filtrate and a
marked decrease in the glomerular capillary ultrafil-
tration coefficient. Stein et al reached similar con-
clusions in micropuncture studies in the dog, per-
formed 48 hr after uranyl nitrate [15]. Thus, from
these data, one might conclude that this nephrotoxic'
agent may have a direct toxic effect on cellular func-
tion independent of changes in renal hemodynamics.
These findings are not meant to imply that a more
potent vasoconstrictor stimulus may not lead to im-
pairment of renal function. In the studies of Flamen-
baum et al [5] and Stein et al [15], a higher dose of
uranyl nitrate (10 mg/kg) was utilized in the dog, and
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renal blood flow was found to decrease 40 to 50% in
the initial six hours after the administration of the
nephrotoxic agent. In pilot studies, we found that
intrarenal PGE infusion did not completely over-
come the vasoconstrictor effect of this larger dose of
uranyl nitrate [18]. In fact, blood flow had returned
to control levels within the three-hour period after
uranyl nitrate (10 mg/kg) despite a concomitant PGE
infusion. Still, inulin clearance fell similarly in the
PGE-infused kidney and the contralateral kidney
where renal blood flow decreased 47% [18]. In any
case, the present study demonstrates that acute renal
functional impairment may occur after administra-
tion of uranyl nitrate in a setting in which renal blood
flow is markedly increased.
In the chronic studies (group 3), renal vasodilata-
tion in the three-hour period after uranyl nitrate did
not prevent a severe reduction in inulin clearance 48
hr later (Table 2). Inulin clearance was equally re-
duced in the experimental and control kidney, 2.7
and 2,5 mI/mm, respectively. Although it is true that
vasoconstriction may have occurred once the PGE
infusion was discontinued, there was still no dis-
cernible effect of markedly reducing renal resistance
during the initial three-hour period when the major
toxic effect of uranyl nitrate would seemingly be
manifest.
As is shown in Figures 2 and 3, there were major
differences in the fractional distribution of renal cor-
tical blood flow in the experimental and control kid-
ney three hours after uranyl nitrate. In the experi-
mental kidney, there was a redistribution of blood
flow to more inner cortical nephrons, as demonstrated
primarily by the fall in fractional distribution of flow
in outer cortical zone I from 42 to 31%. In addition,
the entire increase in total flow as compared with
hydropenic levels was confined to the more inner
cortical nephrons (zones II to IV). It has previously
been demonstrated that renal vasodilatation induced
by PGE administration [19] or other means [20—22]
will cause a redistribution of blood flow to inner
cortical nephrons. Since the redistribution of flow
was noted only in the vasodilated experimental kid-
ney and not in the contralateral kidney where blood
flow tended to decrease, it seems likely that the altera-
tion in regional blood flow was related to the fall in
renal resistance secondary to the PGE infusion and
not to a specific effect of uranyl nitrate. In addition, it
is worthy of reemphasis that a comparable reduction
in inulin clearance occurred three hours after uranyl
nitrate, despite marked differences in both total and
regional blood flow distribution in the two kidneys.
In contrast to the results of the uranyl nitrate stud-
ies, PGE infusion, even for the short period prior to
and during norepinephrine administration (group 5),
had a significant protective effect on the acute change
in inulin clearance three hours after the infusion of
the vasoconstrictor (Table 3). This finding is surpris-
ing since the PGE infusion did not prevent a rapid
and marked fall in renal blood flow during norepi-
nephrine administration. Prior PGE infusion also did
not cause a more rapid restoration of flow than in
group 4 studies (norepinephrine alone), nor did
blood flow ever return to control levels in the group 5
animals. In addition, in the group 6 studies (norepi-
nephrine plus continuous PGE), blood flow was re-
stored more rapidly and did return to control levels at
three hours, but the inulin clearance was no greater in
these studies than in the group 5 animals. The find-
ings in the group 7 studies (norepinephrine plus si-
multaneous PGE) were quite similar to the group 4
studies (norepinephrine alone) and, thus, suggest that
the PGE must be given prior to the norepinephrine in
order to obtain a protective effect. Thus, it would
seem that the infusion of PGE prior to the intrarenal
administration of norepinephrine attenuates the fall
in inulin clearance seen three hours after the infusion
of the vasoconstrictor, but this effect is not amplified
by continuing the PGE after the period of intense
renal vasoconstriction.
It should be emphasized that this protective effect
occurs even though the vasodilator does not alter the
marked increase in renal resistance during norepi-
nephrine infusion. The precise mechanism respon-
sible for this protective effect is not clear from the
present data but may be related to either a direct
hemodynamic effect of the agent or to a more indirect
action, such as the increase in solute excretion which
occurs with the intrarenal infusion of PGE.
These data should not be taken to indicate a spe-
cific role of the prostaglandin system in the patho-
physiology of acute renal failure. PGE was utilized
as the renal vasodilator in this study since it was
found to have the most marked and prolonged effect
of several vasodilators tested. In more recent prelimi-
nary studies from this laboratory, however, other
agents which decrease renal resistance have also been
shown to have a significant protective effect in the
norepinephrine model [23].
In addition, these studies point out the diverse
pathophysiologic alterations which occur in different
experimental models of acute renal failure. Renal
functional impairment occurred in the uranyl nitrate
model in spite of a marked increase in renal blood
flow, suggesting that this agent causes acute renal
failure by a direct toxic effect on cellular function. In
contrast, the acute renal failure seen with intrarenal
norepinephrine infusion was invariably associated
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with a period of intense renal vasoconstriction. POE
infusion modified the acute reduction in inulin clear-
ance seen in this model, but it is not clear whether this
was related to a hemodynamic effect or to a more
indirect action of the drug.
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